HealthNews

The Medicines And Healthcare Products Regulatory Agency In The United Kingdom Has Granted Novavax COVID-19 Vaccine Conditional Marketing Authorization.

Spread the love

Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great Britain
Novavax and the U.K. Vaccines Taskforce previously announced an agreement for up to 60 million doses
Authorization based on data including an ongoing pivotal Phase 3 trial conducted in the U.K. with almost 15,000 participants

Novavax, Inc. , a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization (CMA) for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older in Great Britain. The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine to be authorized for use in Great Britain.

Recommended Articles:-https://prgazette.com/news/glooko-acquires-xbird/

“We are proud that Nuvaxovid will be the first protein-based vaccine option authorized by MHRA as the United Kingdom tackles this next phase of the pandemic,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “We thank the agency for its thorough review process and are tremendously grateful to the clinical trial participants and trial sites in the U.K., as well as the Vaccines Taskforce, for their ongoing support and vital contributions to this program.”

The vaccine we're testing in Australia is based on a flu shot. Here's how  it could work against coronavirus - RMIT University

The MHRA decision was based on the totality of preclinical, clinical, and chemistry, manufacturing and controls (CMC) data reviewed by the agency. This includes two pivotal ongoing Phase 3 clinical trials: PREVENT-19 which enrolled approximately 30,000 participants in the U.S. and Mexico, the results of which were published in the New England Journal of Medicine (NEJM)i; and a trial with almost 15,000 participants in the U.K., the results of which were also published in Novavaxii. In both trials, the vaccine demonstrated efficacy with a reassuring safety profile. Serious and severe adverse events were low in number and balanced between vaccine and placebo groups. The most common adverse reactions observed during clinical studies (frequency category of very common ≥1/10) were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise. Novavax will continue to collect and analyze real-world data, including the monitoring of safety and the evaluation of variants, as the vaccine is distributed. The vaccine is stored at 2° – 8° Celsius and has a current assigned shelf life in Great Britain of 9 months.

Novavax previously announced an agreement with the U.K. Vaccines Taskforce for up to 60 million doses of Novavax’ COVID-19 vaccine.

For more information on Nuvaxovid, including a full listing of where it has been authorized for use, please visit the following websites:

  • MHRA Regulatory approval of COVID-19 vaccine Nuvaxovid
  • Novavax global authorization website

The brand name Nuvaxovid™ has not yet been authorized for use in the U.S. by the FDA.

Recommended Articles:-https://prgazette.com/news/alira-health/

Conditional Marketing Authorization of Nuvaxovid in Great Britain
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorization for Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.

Novavax Says Its COVID Vaccine Is Extremely Effective : Coronavirus Updates  : NPR

Important Safety Information

  • Nuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.
  • Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of Nuvaxovid.
  • Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation, or stress–related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that precautions are in place to avoid injury from fainting.
  • Vaccination should be postponed in individuals suffering from an acute severe febrile illness or acute infection. Minor infection and/or low-grade fever should not delay vaccination.
  • Nuvaxovid should be given with caution in individuals receiving anticoagulant therapy or those with thrombocytopenia or any coagulation disorder (such as hemophilia) because bleeding or bruising may occur following an intramuscular administration in these individuals.
  • The efficacy of Nuvaxovid may be lower in immunosuppressed individuals.
  • The effects with Nuvaxovid may temporarily affect the ability to drive or use machines.
  • Individuals may not be fully protected until 7 days after their second dose. As with all vaccines, vaccination with Nuvaxovid may not protect all vaccine recipients.
  • The most common adverse reactions observed during clinical studies (frequency category of very common ≥1/10) were headache, nausea or vomiting, myalgia, arthralgia, injection site tenderness/pain, fatigue, and malaise.

For additional information, for the full Summary of Product Characteristics with Package Leaflet, Prescribing Information and Important Safety Information, adverse event reporting instructions, or to request additional information.


Spread the love

Craig Hill

Craig began writing for prgazette.com in 2005, resulting in engaging and fascinating editorials about science and wellness progress. Craig’s inspirational and accurate science and health articles have made her very popular with the viewers. Craig graduated at the University of Illinois at Urbana-Champaign with a Bachelor of Arts degree at October in 2004. He then completed a science college internship in Fermilab, followed using a communications internship in Caterpillar. Ever since that moment, he has been writing in an independent capability for several science, health, technology, along with other books.

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button